IDEAS home Printed from https://ideas.repec.org/a/spr/scient/v88y2011i2d10.1007_s11192-011-0403-0.html
   My bibliography  Save this article

Top Journals Selectivity Index: is it acceptable for drugs beyond the field of analgesia?

Author

Listed:
  • Igor Kissin

    (Brigham and Women’s Hospital, Harvard Medical School)

  • Edwin L. Bradley

    (University of Alabama)

Abstract

To predict the success of an analgesic drug we have suggested a bibliometric indicator, the Top Journals Selectivity Index (TJSI) (Kissin, Scientometrics, 86:785–795, 2011). It represents the ratio (as %) between the number of all types of articles on a particular drug in the top 20 biomedical journals and the number of articles on that drug in all (>5,000) journals covered by Medline over the first 5 years after a drug’s introduction. For example, the highest TJSI score among analgesics was that of sumatriptan, the most successful drug for the treatment of migraine. The aim of this study was to demonstrate that TJSI may be used not only in the field of analgesics, but also for various other categories of drugs. The study tested two hypotheses. First, the difference between the most successful and less successful drugs in any pharmacological class can be reliably detected by TJSI. Second, drugs with TJSI indicators as high as that of sumatriptan can be found among other pharmacological classes as well. Drugs from various pharmacological classes approved by the Federal Drug Administration (FDA) during the 10-year period, 1980–1989, were used in this study. Two groups of 10 drugs were selected to test the first hypothesis. One group included the most successful (breakthrough) drugs; the other included less successful drugs matched with the breakthrough drugs according to mechanism of action. The difference between the two groups was compared using three publication indices: the TJSI, the number of all types of articles on a drug in journals presented by Medline (AJI), and the number of articles covering only randomized controlled trials (RCT). It was found that TJSI can detect the difference between the two groups of drugs better than the two other indices. TJSI detected the difference between a breakthrough drug and its less successful counterpart at least 69% of the time with 95% confidence. With the other two indices the difference was not distinguishable from random chance. Some of the breakthrough drugs (zidovudine, omeprazole, lovastatin) have TSJIs as high or even higher than that of sumatriptan (19.2 vs. 23.0, 21.4, and 20.6, respectively). In conclusion, TJSI can be useful not only in the field of analgesics, but also with drugs belonging to other pharmacological classes.

Suggested Citation

  • Igor Kissin & Edwin L. Bradley, 2011. "Top Journals Selectivity Index: is it acceptable for drugs beyond the field of analgesia?," Scientometrics, Springer;Akadémiai Kiadó, vol. 88(2), pages 589-597, August.
    • Handle: RePEc:spr:scient:v:88:y:2011:i:2:d:10.1007_s11192-011-0403-0
    DOI: 10.1007/s11192-011-0403-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s11192-011-0403-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s11192-011-0403-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Igor Kissin & Edwin L. Bradley, 2012. "Top journals selectivity index and “me-too” drugs," Scientometrics, Springer;Akadémiai Kiadó, vol. 91(1), pages 131-142, April.
    2. Ricardo Arencibia-Jorge & Elena Corera-Alvarez & Zaida Chinchilla-Rodríguez & Félix Moya-Anegón, 2016. "Scientific output of the emerging Cuban biopharmaceutical industry: a scientometric approach," Scientometrics, Springer;Akadémiai Kiadó, vol. 108(3), pages 1621-1636, September.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:scient:v:88:y:2011:i:2:d:10.1007_s11192-011-0403-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.